Skip to content
Graymedy Health technology human perspective
English
English Arabic
  • Home
  • Professionals
  • Dr Aayush Gupta: connecting dermatology care with research into skin and healing
Professionals

Dr Aayush Gupta: connecting dermatology care with research into skin and healing

The Professional Profile

Dr Aayush Gupta. Portrait: Aayushg387, Wikimedia Commons, CC BY SA 4.0. Illustrative scalp examination: Hülya Ermiş Belek, Pexels. Graymedy editorial layout.
Dr Aayush Gupta. Portrait: Aayushg387, Wikimedia Commons, CC BY SA 4.0. Illustrative scalp examination: Hülya Ermiş Belek, Pexels. Graymedy editorial layout.

GRAYMEDY PROFESSIONAL PROFILE

For Dr Aayush Gupta, dermatology reaches from the questions patients bring into a consultation to the laboratory work that may one day change how skin disease is understood. His work spans pigment disorders, wound care and the experience of pain during procedures. These areas may seem distant, but each begins with a practical problem: how can clinicians make care more useful for the people receiving it?

Gupta is professor and head of the Department of Dermatology, Venereology and Leprosy at Dr D. Y. Patil Medical College, Hospital and Research Centre in Pimpri, Pune. The institution lists him as a physician with an MBBS and an MD in dermatology. Its October 2026 faculty record identifies him as head of the department.

At a glance

Profession: Dermatologist, researcher and educator
Institution: Dr D. Y. Patil Medical College, Hospital and Research Centre, Pune, India
Areas of work: Pigment disorders, wound care, clinical research and dermatology technology
Profile basis: Public institutional records, research publications and the professional’s published profile

A clinical discipline with many layers

Dermatology often enters public conversation through skincare routines or cosmetic procedures. The department Gupta leads also encompasses infections, inflammatory disease, pigment changes and conditions with effects that extend beyond the skin. Its name reflects a broad clinical remit, including leprosy and venereology.

The college’s research list places Gupta alongside projects in vitiligo, rare genetic skin disease, skin transplantation and leprosy. These projects are listed as ongoing in the institution’s published record. A project listing establishes a research question and an institutional commitment; it does not establish that a treatment works or is available to patients.

That distinction is especially important in a field where laboratory findings and commercial claims can travel quickly. A biological idea must be tested for safety, effectiveness and practicality before it can become a dependable part of care.

Investigating vitiligo at the cellular level

Vitiligo causes areas of skin to lose pigment. For researchers, it also raises questions about how skin cells respond to ultraviolet exposure when pigment is reduced. Gupta is a coauthor of a 2026 study in Scientific Reports examining a small regulatory molecule and its relationship to ultraviolet damage in skin cells associated with vitiligo.

The team investigated a pathway involving a microRNA, a protein called SP1 and cellular processes involved in repair. The paper adds to biological understanding of how these cells respond under experimental conditions. It does not show that a new sunscreen or treatment is ready for patients, and it does not replace established advice on sun protection.

Gupta also appears among the authors of a 2024 analysis examining ultraviolet signatures in vitiligo skin and nonmelanoma skin cancers. Both papers reflect collaborative research. Their findings belong to the research teams and should be read within each study’s design, rather than attributed to one physician alone.

What a wound can reveal about a technology

A separate 2025 pilot study brought Gupta and colleagues to a different question: could imaging help guide care for chronic leg ulcers in people with leprosy? The researchers used a device that combines multispectral imaging with artificial intelligence to help identify areas for wound cleaning.

The study enrolled five adult men, each with at least two ulcers. One ulcer per participant was assigned to imaging guided care and another to standard care. Over 18 weeks, the researchers reported a greater average reduction in wound area in the imaging group. One ulcer in each group closed completely, with the imaging group ulcer closing sooner.

Those results are worth investigating because they connect a technological measurement to the everyday challenge of wound management. They are also preliminary. Five participants cannot establish how well the approach works across different patients and settings. The authors called for larger, blinded studies. The pilot should not be read as proof that a device replaces clinical judgement or standard treatment.

Making procedures more comfortable

Another strand of Gupta’s published work concerns the patient experience during dermatologic procedures. A study published in 2026 compared similar procedure sites in 629 patients, using a vibrating device at one site and no vibration at the other. The authors reported lower pain scores with vibration and a strong patient preference for its use.

The comparison is useful because each person contributed sites to both approaches. It was nevertheless an observational study, and its results do not mean vibration will work equally well for every procedure or patient. Independent replication and comparison with other pain management options would help clarify where the approach is most useful.

There is also a commercial connection readers should know. Gupta’s profile on Springer Nature’s research community identifies him as founder of Qtanea Solutions, which developed a vibration device. That relationship is relevant context when assessing research in this area. This article does not recommend a product or imply that Graymedy has a commercial relationship with him.

From research questions to patient care

The range of Gupta’s work illustrates how a dermatologist can participate in several parts of medical progress: seeing patients, teaching clinicians, collaborating with laboratory scientists and evaluating tools intended for care. The evidence for each project must still stand on its own.

For a reader considering a consultation, the most useful questions remain personal and specific: what is causing the change I have noticed, what options are appropriate for me, and what are their likely benefits and limitations? A professional profile can introduce a clinician’s work, but it cannot establish a diagnosis or guarantee a particular result.

Editorial note: This is an independent profile based on public sources. Graymedy did not interview Dr Gupta for this article. The profile is not a paid placement or a clinical endorsement.

Sources and image

Dr D. Y. Patil Medical College faculty record and department research outcomes; vitiligo cell study, Scientific Reports, 2026; leprosy ulcer imaging pilot, 2025; vibration and procedure pain study, 2026; Springer Nature research community profile.

Portrait: Aayushg387 via Wikimedia Commons, CC BY SA 4.0. Portrait resized and placed in a Graymedy branded layout.

Professionals

View more
Nabila El-Bassel: HIV prevention and social work research. AI-assisted editorial graphic based on a Bruce Gilbert / Columbia University portrait; background is conceptual.
Nabila El-Bassel: bringing HIV prevention and addiction care closer to communities

For social work researcher Nabila El-Bassel, access to health care depends on more than whether an effective treatment exists. Services must be reachable and responsive to the circumstances of the people who need them. Her research examines HIV prevention, substance use and the social conditions that can make care difficult to obtain. El-Bassel is a University Professor and the Willma and Albert Musher Professor of Social Work at Columbia University. Columbia identifies her as director of the Social Intervention Group and the Global Health Research Center of Central Asia. Her work has included designing and testing HIV and substance-use interventions in settings ranging from primary care and harm reduction programs to the criminal justice system. Taking services closer to people A recent example is HPTN 094, a randomized trial co-chaired by El-Bassel and Steven Shoptaw. The NIH-funded study enrolled 409 adults without HIV in Houston, Los Angeles, New York City, Philadelphia and Washington, D.C. Participants injected drugs, had opioid use disorder, were not receiving medication for that disorder at enrollment and were willing to consider it. Both groups received 26 weeks of peer navigation. In one group, participants could also obtain integrated HIV prevention, medication for opioid use disorder, and limited clinical and supportive services through a mobile medical unit. The comparison group received peer navigation linking them to available community services outside the mobile units. The design therefore tested an integrated delivery model against an active navigation approach, not against no help at all. The practical distinction matters. A referral can connect someone to a service, but it may still require another journey, appointment or interaction with a separate organization. A mobile unit brings several services into one setting. The trial asked whether that arrangement could improve outcomes for people who face barriers to sustained care. Reading the results carefully NIH reported 71% lower all-cause mortality in the mobile-services group. Mortality was a secondary outcome, however, and the investigators found no difference between groups in use of daily oral HIV pre-exposure prophylaxis, or PrEP, or medication for opioid use disorder. NIH said the mortality finding requires replication. Those results should be held together. The mortality signal is important and deserves further study, but it does not establish which component of the combined intervention caused the difference. Nor does it show that mobile units improved every outcome measured. The comparison involved a particular group in five cities and cannot automatically predict results in other communities. NIH also reported that verified oral PrEP use was low at 26 weeks. Fourteen percent of participants used medication for opioid use disorder at 26 and 52 weeks, a meaningful level in a population where none was receiving it at the start, although use did not differ between the groups. The researchers pointed to the need to investigate long-acting PrEP options in this population. Research across disciplines Columbia describes the Social Intervention Group as a multidisciplinary center that develops, tests and disseminates prevention and intervention approaches. El-Bassel’s work has addressed the intersection of HIV, substance use and gender-based violence, including interventions for women, men and couples. Columbia also describes her work mentoring HIV researchers and training scientists in intervention and prevention research. Her role at the Global Health Research Center of Central Asia extends that perspective across locations. Columbia describes a team working in New York and Central Asia on health and social issues through research, education, training, policy and dissemination. The details of a program must fit its local context, but the larger research question is shared: how can evidence-based services reach people who are often excluded from conventional pathways? HPTN 094 shows the value of asking that question in a controlled study. It also shows why a headline result needs its limits. Replication, attention to service uptake and understanding what participants actually need are necessary before a promising delivery model can be judged across different settings. Sources: Columbia School of Social Work profile; NIH trial announcement, November 4, 2026; Shoptaw, El-Bassel and colleagues, JAMA Psychiatry. Image: AI-assisted Graymedy editorial graphic based on a 2019 portrait of Nabila El-Bassel by Bruce Gilbert, published by Columbia University (https://president.columbia.edu/news/el-bassel-university-professor). The background is conceptual. This independent profile is based on public sources; no interview is implied.

Graymedy Editorial November 16, 2026 0
Dr Shamsheer Vayalil. AI-assisted Graymedy illustration based on a portrait by Kcmazin / Wikimedia Commons, CC0 1.0; illustrative background.

Dr Shamsheer Vayalil: from radiology to building connected healthcare

Dr Jon Bloom: diabetes foot care and remote monitoring. AI-assisted Graymedy editorial graphic based on a Podimetrics portrait; background is conceptual.

Dr Jon Bloom: connecting diabetes foot care with technology and human support

Dr Aayush Gupta. Portrait: Aayushg387, Wikimedia Commons, CC BY SA 4.0. Illustrative scalp examination: Hülya Ermiş Belek, Pexels. Graymedy editorial layout.

Dr Aayush Gupta: connecting dermatology care with research into skin and healing

Dr. Kaitlyn Sadtler facing the camera in a white lab coat, with her arms folded in her laboratory.
Dr. Kaitlyn Sadtler: teaching biomaterials to work with the immune system

Repairing damaged tissue requires more than finding a material that fits. The body must decide how to respond to it. That meeting between an implant and the immune system is the focus of Dr. Kaitlyn Sadtler’s work at the National Institute of Biomedical Imaging and Bioengineering. The response around the material NIH identifies Sadtler as a senior investigator leading its Section on Immunoengineering. Her group studies how immune responses influence reconstruction after traumatic soft-tissue injury, including whether implanted scaffolds integrate with tissue or provoke harmful inflammation and fibrosis. Its approach combines biomaterials with studies of immune mechanisms. A scaffold can provide a structure for repair, but structure alone is not a complete biological explanation. Researchers also need to understand the cells and signals that arrive around it. This makes the work relevant to a practical engineering question: what should a material encourage the surrounding tissue to do? From mechanisms to useful questions Sadtler trained at Johns Hopkins and completed postdoctoral work at MIT before establishing her NIH laboratory. Her published research includes studies of immune-regulating dendritic cells after traumatic injury and of responses to biologic scaffold implantation. NIBIB highlighted her interdisciplinary work when she was named to the TIME100 Next list in 2024. Those dates matter. This is a professional profile selected for today’s edition, not an announcement of a new award or an approved regenerative treatment. A laboratory mechanism can suggest a direction for development without establishing that a particular implant improves recovery in patients. What makes the work worth following Graymedy’s interest is in the connection between engineering and healing. The most useful next questions concern durable tissue function, safety and reproducibility, rather than whether a material looks promising in isolation. A successful laboratory result still needs a clear route to clinical testing and evidence that matters to people living with injury. The photograph is an official NIH laboratory portrait of Dr. Kaitlyn Sadtler. Sources and image credit NIH investigator profile and selected publications; NIBIB profile, October 21, 2024. Editorial review: November 9, 2026. Independent profile based on public sources; no interview or endorsement is implied. Photo: NIH / NIBIB. Official investigator portrait and profile.

Graymedy Editorial November 9, 2026 0
Dr Hui Zhang — AI-generated editorial portrait based on a Complete Omics photograph.

Dr Hui Zhang: reading cancer’s protein signals before claiming a clinical answer

From Research to Reach podcast cover featuring Dr. Kristin Higgins, Dr. Alan Bryce and host Dr. Monty Pal, with a microphone and waveform

From research to reach: Dr. Alan Bryce and Dr. Kristin Higgins on cancer care closer to home

Dr John Tisdale in an archival NIH laboratory photograph, with Graymedy Doctor Spotlight name and hematology specialty

Dr John Tisdale: the next sickle-cell breakthrough must be easier to reach

High-resolution archival portrait of Dr Steven Rosenberg in his NCI laboratory, with Graymedy Doctor Spotlight lettering
Dr Steven Rosenberg: trying to make personalised cell therapy work for more solid cancers

Dr Steven Rosenberg is pursuing a difficult extension of cancer immunotherapy: making a person’s own immune cells effective against more of the common cancers that form solid tumours. The ambition reaches beyond celebrating an earlier breakthrough. It concerns patients whose cancers have continued to grow despite several treatments and whose next options remain limited. At the U.S. National Cancer Institute, Rosenberg’s programme brings laboratory selection of immune cells into clinical trials. Its most interesting feature is the effort to make personalisation experimentally useful: identify cells that recognise an individual tumour, increase their numbers, and test whether they can produce a meaningful response. A long pursuit with a current obstacle NCI’s current profile lists Rosenberg as chief of its Surgery Branch. His work helped establish that manipulating the immune system can cause cancer regression. An NIH historical account describes the early investigation of interleukin-2 and the development of approaches using tumour-infiltrating lymphocytes, usually called TILs. These are immune cells already found within a tumour. Their presence creates an opportunity, but does not establish that every cell collected will attack cancer effectively. NCI’s patient guidance explains that researchers can test and select lymphocytes that recognise tumour cells, then expand them in the laboratory before infusion. This is the research problem behind the personalised label. The task involves identifying useful activity and preserving it through a demanding treatment process. Simply giving more cells is not the same as giving cells with the right recognition capabilities. Selecting the cells that matter In April 2025, Rosenberg and colleagues reported a phase 2 study involving 91 people with metastatic gastrointestinal cancers. Participants had previously received a median of four treatment regimens. The programme examined successive approaches, including unselected TILs, selected TILs, and selected TILs combined with pembrolizumab. NCI reported no objective responses among 18 recipients of unselected cells. Responses occurred in three of 39 people receiving selected TILs and eight of 34 receiving selected TILs plus pembrolizumab. The combination result was 23.5%, a signal worth investigating in cancers that had proved difficult to treat. The groups were sequential parts of a developing programme, rather than a simple randomised comparison establishing the contribution of each change. Tumour shrinkage also differs from a demonstrated survival advantage. These limits belong beside the result, particularly in a profile of a researcher associated with major advances. The next breakthrough is more specific The team’s stated next direction includes improving identification of cells that recognise several tumour-specific neoantigens. These are targets associated with a cancer’s mutations. The aim is to increase the proportion of patients who respond, rather than assuming that the existing approach already works broadly. A separate NCI report from July 2024 described another route: transferring personalised, tumour-reactive T-cell receptors into a patient’s blood-derived immune cells. In a small colorectal-cancer study, three of seven patients responded. The result supplied proof of possibility and a reason for refinement, not a universal solid-tumour treatment. These approaches share a question about recognition. Can researchers identify the molecular features that make a particular cancer vulnerable, then create a cell product able to act on that information? The answer must come from reproducible clinical results across appropriately designed studies. Why the difficult parts matter Cell therapy is an intensive pathway involving collection, laboratory work, preparatory treatment and specialist monitoring. NCI’s guidance describes weeks of cell growth and treatment to reduce competing immune cells before infusion. This places manufacturing and patient fitness within the scientific challenge, rather than treating them as administrative details. Safety is equally central. The 2025 report describes serious side effects in 30% of patients treated with selected TILs. A stronger antitumour response would have to be considered alongside those harms and the experience of undergoing the full regimen. Existing approvals must also be kept separate from experimental extensions. Lifileucel has an approved role in advanced melanoma. That does not establish approval of the personalised gastrointestinal-cancer approaches described here. A familiar therapeutic family can contain both established treatments and early research programmes. A researcher to follow for the next question Graymedy’s reading of Rosenberg’s work is that the pursuit remains compelling because it keeps narrowing a large ambition into testable decisions: which target, which cells, which combination and which patients. Progress depends on improving those decisions together. The potential breakthrough would be a reliably effective, tolerable and deliverable personalised treatment for more solid cancers. Rosenberg and his collaborators have produced signals that justify continuing that search. Its unfinished nature is precisely what makes this a research story worth following. Sources: NCI: current investigator profile; NIH Catalyst: historical research profile; NCI: gastrointestinal-cancer TIL trial, April 2025; NCI: personalised TCR trial, July 2024; NCI: cell-transfer treatment context. Photo: Rhoda Baer / National Cancer Institute, 2008. Reviewed 4 November 2026. Independently written from public sources; no interview was conducted. General information, not individual medical advice.

Graymedy Editorial November 4, 2026 0
Kizzmekia Corbett-Helaire beside molecular protein models in a January 2020 NIH interview, with Graymedy Researcher Spotlight lettering

Kizzmekia Corbett-Helaire: designing vaccines before the next outbreak

Dr Michelle Monje in her laboratory, with Graymedy Doctor Spotlight name and pediatric neuro-oncology specialty

Dr Michelle Monje: decoding the conversation between brain and cancer

Healthcare professionals discussing clinical care

The Quiet Expertise Behind Safer Hospital Handoffs

STAY INFORMED

Notifications

New stories, news and e-newspapers, as they become public.

Browser notifications

Get an alert on this device when we publish. You can turn this off anytime.

Loading notification settings…

Latest updates

No new publications yet. Check back soon.